Did you know? You can suggest edits to improve this peptide information.
Overview
What is Cagrilintide?
Cagrilintide (AM833) is a novel long-acting lipidated amylin analog that acts as a dual amylin and calcitonin receptor agonist. Developed for weight management and type 2 diabetes treatment, it shows superior weight loss potential when combined with semaglutide (CagriSema), with recent Phase 3 trials demonstrating up to 22.7% weight reduction.
Key Benefits
FDA development candidate, extensive Phase 3 data, superior weight loss in combination with semaglutide, once-weekly convenience
Mechanism of Action
Subcutaneous injection provides optimal bioavailability of lipidated amylin analog, targeting dual amylin and calcitonin receptors for satiety and metabolic effects
Molecular Information
Weight
4,409.01 Da
Length
37 amino acids
Type
Amylin receptor agonist
Amino Acid Sequence:
Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Pro-Ile-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH₂
* N-terminal lipidation with γ-glutamic acid spacer and C20 fatty diacid
Pharmacokinetics
Research Indications
Superior Obesity Treatment
Phase 3 trials demonstrate 22.7% weight loss with CagriSema combination, outperforming existing therapies
Type 2 Diabetes Weight Management
15.7% weight loss in diabetic patients with concurrent glycemic improvements
Sustained Weight Maintenance
Long-acting formulation supports sustained weight loss throughout treatment period
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Administer same day each week. Evening injection may reduce morning nausea. Can be given with or without food due to subcutaneous route.
Peptide Interactions
How to Reconstitute
Important
pH CRITICAL: Cagrilintide requires acidic pH (3.5-4.5) to prevent fibril formation. Standard BAC water (pH 5.5-6) is acceptable for short-term use (<30 days). For optimal long-term stability, acidify to pH ~4.0 with 0.6% acetic acid.
Reconstitute slowly down side of vial, swirl gently (don't shake)
Verify solution is clear - any cloudiness or particles indicates fibril formation, discard immediately
Store refrigerated (2-8°C), inspect for clarity before each injection
Allow to reach room temperature 15-30 minutes before injection
Inject subcutaneously in abdomen, thigh, or upper arm, rotating sites weekly
Quality Indicators
Pre-filled pen design
When approved, will likely be available as convenient pre-filled pen similar to other Novo Nordisk products
Pharmaceutical grade purity
Clinical trial material demonstrates >98% purity with appropriate lipidation and folding
Frozen storage stability
Proper frozen storage at -20°C maintains stability of lipidated peptide structure
Extended stability profile
Long-acting formulation provides stable pharmacokinetics over 7-day dosing interval
Fibril formation at improper pH
Amylin analogs have inherent tendency to form amyloid fibrils, especially at neutral or alkaline pH. Solution should remain clear - any cloudiness, visible particles, or gel-like texture indicates fibril formation and the product should be discarded immediately
Aggregation or precipitation
Any visible particles, cloudiness, or color changes indicate protein degradation
Temperature excursions
Exposure to repeated freeze-thaw cycles or high temperatures can denature the peptide structure
pH-dependent stability - reconstitution concerns
Cagrilintide requires acidic formulation (pH 3.5-4.5) for optimal stability. Reconstitution with standard bacteriostatic water (pH 5.5-6) is acceptable for short-term use (<30 days refrigerated) but may cause gradual degradation. Higher pH environments can lead to deamidation and protein aggregation. Pharmaceutical formulations use pH ~4.0 for maximum stability
Not yet commercially available
Currently only available in clinical trials - FDA approval expected Q1 2026
What to Expect
- Week 1-2: Gastrointestinal adaptation period, mild nausea possible during dose escalation
- Week 4-8: Early weight loss becomes apparent (2-5%), appetite reduction noticeable
- Week 12-26: Significant weight loss acceleration (10-15%), improved satiety signals
- Week 26+: Peak efficacy achieved (15-23% weight loss), sustained weight loss maintenance with continued therapy
Side Effects & Safety
- Most common side effects are gastrointestinal (nausea, vomiting, diarrhea) during initial weeks
- Anti-cagrilintide antibodies develop in 46-73% of patients but do not affect efficacy
- No clinically significant QT prolongation observed in thorough QT studies
- Only 57.3% of patients achieved maximum 2.4 mg dose in REDEFINE 1 trial
- Formulation must be maintained at acidic pH (3.5-4.5) to prevent fibril formation and deamidation. Reconstituted solutions should be inspected for cloudiness or particles before each use
References
REDEFINE 1 Trial - Phase 3 Weight Loss (2025)
Landmark Phase 3 trial published in NEJM demonstrating superior weight loss with CagriSema combination in 3,417 adults with obesity, achieving primary endpoints with excellent safety profile
View Study (opens in new tab) →REDEFINE 2 Trial - Phase 3 Type 2 Diabetes (2025)
Phase 3 trial in 1,206 adults with type 2 diabetes and obesity published in NEJM, demonstrating significant weight loss and glycemic improvements with CagriSema
View Study (opens in new tab) →Thorough QT Study - Cardiac Safety (2024)
Dedicated cardiac safety study confirming no significant QT interval prolongation at supratherapeutic doses, supporting cardiovascular safety profile
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia